New hope for lung cancer patients whose targeted therapy stopped working
NCT ID NCT07158840
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 21 times
Summary
This study tests a new drug called AK112 in people with a specific type of lung cancer (non-squamous non-small cell) that has certain genetic changes. Participants must have already tried and failed a standard targeted therapy (TKI). The goal is to see if AK112 can shrink tumors or slow the cancer. About 60 adults aged 18–75 will take part at multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.